Citi analyst Yigal Nochomovitz lowered the firm’s price target on Oric Pharmaceuticals to $8 from $9 and keeps a Buy rating on the shares. The analyst updated biotechnology models following the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ORIC:
- ‘Charts Point to Higher Highs,’ Says Oppenheimer. Here’s a Stock With Over 100% Upside Potential
- Oric Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
- Oric Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
- Oric Pharmaceuticals reports Q4 EPS (52c), consensus (55c)
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates